Prelude Therapeutics Inc

PRLD

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001678660

SEC filings (opens in a new tab)

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026: $275.3M
Insider buysOpen market, last 90 days: 0
Insider sellsOpen market, last 90 days: 0
13F holdersQ2 2026, +21 vs. previous quarter: 75
13F valueReported value at the end of Q2 2026: $264.3M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $12.1M; +73.4% year over year
Net income, FY2025: -$99.5M; No comparable prior period
Free cash flow, FY2025: -$56.4M; No comparable prior period
Revenue, Q2 FY2026: $5.70M; No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $99.5M (819.6% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 4.18M; Shares sold short
Change: −919.9K; −18.1% vs. previous
Days to cover: 9.14; At average daily volume

Superinvestors holding PRLD, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding PRLD at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Prelude Therapeutics Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Apr 23, 2026 (view filing)6:48 PM ET	Apr 21	2 days	OrbiMed Advisors LLC and 3 othersDirector, 10% Owner	PPurchase	+2.82M	$4.44	+$12.5M	New position1.13M after	2 lotsDuplicate filing
Apr 23, 2026 (view filing)	Apr 21	2 days	Bonita David PDirector, 10% Owner	PPurchase	+2.82M	$4.44	+$12.5M	New position1.13M after	2 lots
Apr 22, 2026 (view filing)4:15 PM ET	Apr 21	1 day	Baker Julian and 5 othersDirector, 10% Owner	PPurchase	+2.25M	$4.44	+$10.0M	–20.1M after	Derivative2 lots
Mar 27, 2025 (view filing)	Mar 25	2 days	Combs AndrewChief Chemistry Officer	PPurchase	+100.0K	$0.69	+$69.0K	+26.3%480.1K after
Mar 27, 2025 (view filing)	Mar 25	2 days	Vaddi KrishnaCEO	PPurchase	+675.0K	$0.69	+$465.8K	+51.0%2.00M after
Mar 24, 2025 (view filing)	Mar 20-21	4 days	Vaddi KrishnaCEO	PPurchase	+20.4K	$0.73	+$14.9K	+1.6%1.32M after	2 lots
Mar 18, 2025 (view filing)	Mar 14-17	4 days	Vaddi KrishnaCEO	PPurchase	+39.1K	$0.75	+$29.3K	+3.1%1.30M after	2 lots
Mar 14, 2025 (view filing)	Mar 12-13	2 days	Vaddi KrishnaCEO	PPurchase	+97.5K	$0.7151	+$69.7K	+8.4%1.26M after	2 lots
Jan 3, 2025 (view filing)	Dec 31, 2024	3 days	Vaddi KrishnaCEO	PPurchase	+5.00K	$1.21	+$6.05K	+3.6%142.6K after
Jan 2, 2025 (view filing)	Dec 30, 2024	3 days	Vaddi KrishnaCEO	PPurchase	+10.0K	$1.20	+$12.0K	+7.8%137.6K after

Top 10 13F holders, Q2 2026

See all 75 holders

The largest institutional positions in Prelude Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding PRLD in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
OrbiMed Advisors LLC	13,724,571	$73.2M	1.39%	+2,815,315+25.8%	Added
Baker Bros. Advisors LP	10,123,824	$54.0M	0.27%	00.0%	Unchanged
Ra Capital Management, L.P.	6,475,882	$34.5M	0.30%	+6,475,882	New
Soleus Capital Management, L.P.	3,378,378	$18.0M	0.62%	+3,378,378	New
Kynam Capital Management, LP	2,415,087	$12.9M	0.71%	+822,536+51.6%	Added
Vanguard Capital Management LLC	2,009,445	$10.7M	0.00%	+779,039+63.3%	Added
BlackRock, Inc.	1,797,501	$9.58M	0.00%	+1,475,615+458.4%	Added
Sphera Funds Management Ltd.	1,019,832	$5.44M	0.78%	+461,493+82.7%	Added
Two Sigma Investments, LP	993,369	$5.29M	0.00%	+69,743+7.6%	Added
ADAR1 Capital Management, LLC	900,900	$4.80M	0.23%	+748,075+489.5%	Added

Holders of 5% or more of PRLD

See all 6 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Prelude Therapeutics Inc.

Largest holders of PRLD from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
OrbiMed Advisors LLC	13D/A	16.00%12.9M shares	–	Jan 14, 20213 filings	Apr 23, 2026	SEC
Baker Bros. Advisors LP	13D/A	15.50%10.3M shares	−8.00 ppfrom 23.50%	Jan 29, 20215 filings	Apr 22, 2026	SEC
Vaddi Krishna	13G/A	13.15%6.75M shares	−0.65 ppfrom 13.80%	Feb 11, 20217 filings	Feb 13, 2026	SEC
Ra Capital Management, L.P.	13G	9.90%6.48M shares	New	Apr 28, 20261 filing	Apr 28, 2026	SEC
Incyte Corp	13G	9.90%4.37M shares	New	Nov 7, 20251 filing	Nov 7, 2025	SEC